Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Luís Felipe Campesato1,2,3, Romualdo Barroso-Sousa2, Leandro Jimenez1,2, Bruna R. Correa2, Jorge Sabbaga2, Paulo M. Hoff2, Luiz F. L. Reis2, Pedro Alexandre F. Galante2 and Anamaria A. Camargo1,2 1 Instituto Ludwig de Pesquisa sobre o Câncer, São Paulo, Brazil 2 Hospital Sírio-Libanês, São Paulo, Brazil 3 Departmento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil Correspondence to: Anamaria A. Camargo, email: // <![CDATA[ mail("aacamargo","mochsl.org",70,"") // ]]> Keywords: cancer-gene panels, mutational load, PD-1 blockade, immunotherapy, response prediction Received: August 04, 2015 Accepted: September 04, 2015 Published: October 01, 2015